Galmed Pharmaceuticals Ltd Cash Flow Conversion Efficiency
Galmed Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Galmed Pharmaceuticals Ltd (GLMD) has a cash flow conversion efficiency ratio of -0.167x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.13 Million) by net assets ($12.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Galmed Pharmaceuticals Ltd (2012–2025)
Cash flow conversion efficiency of Galmed Pharmaceuticals Ltd from 2012 to 2025. This chart illustrates how Galmed Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Galmed Pharmaceuticals Ltd share price for real-time trading data and today's change.
Galmed Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained
Galmed Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Galmed Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galmed Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see Galmed Pharmaceuticals Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adslot Ltd
AU:ADS
|
0.013x |
|
FUTURE METALS NL
F:3R10
|
N/A |
|
Bumi Citra Permai Tbk
JK:BCIP
|
-0.010x |
|
ARGO GOLD INC.
F:P3U
|
0.038x |
|
Borneo Olah Sarana Sukses PT
JK:BOSS
|
0.380x |
|
Sdcl Energy Efficiency Income Trust PLC
LSE:SEIT
|
0.018x |
|
OCEAN-GEOLOOP AS NK -01
F:FQ4
|
N/A |
|
Sungshin Cement Co Ltd
KO:004985
|
0.075x |
Annual Cash Flow Conversion Efficiency for Galmed Pharmaceuticals Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Galmed Pharmaceuticals Ltd from 2012 to 2025. Review Galmed Pharmaceuticals Ltd leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.78 Million | $-6.32 Million | -0.400x | -11.11% |
| 2024-12-31 | $16.33 Million | $-5.88 Million | -0.360x | +18.55% |
| 2023-12-31 | $13.88 Million | $-6.14 Million | -0.442x | +67.92% |
| 2022-12-31 | $13.42 Million | $-18.50 Million | -1.378x | -27.79% |
| 2021-12-31 | $30.50 Million | $-32.89 Million | -1.079x | -81.16% |
| 2020-12-31 | $44.15 Million | $-26.29 Million | -0.595x | -178.42% |
| 2019-12-31 | $69.85 Million | $-14.94 Million | -0.214x | -108.30% |
| 2018-12-31 | $87.89 Million | $-9.02 Million | -0.103x | +86.56% |
| 2017-12-31 | $15.79 Million | $-12.07 Million | -0.764x | +30.24% |
| 2016-12-31 | $11.07 Million | $-12.13 Million | -1.095x | -178.44% |
| 2015-12-31 | $21.55 Million | $-8.47 Million | -0.393x | -33.67% |
| 2014-12-31 | $31.41 Million | $-9.24 Million | -0.294x | -122.74% |
| 2013-12-31 | $-1.95 Million | $-2.52 Million | 1.294x | -16.85% |
| 2012-12-31 | $-1.98 Million | $-3.08 Million | 1.556x | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more